Skip to main content
Fig. 6 | Cost Effectiveness and Resource Allocation

Fig. 6

From: Cost-utility analysis of olaparib assisted targeted therapy for BRCA mutation HER2-negative early breast cancer in China and in the United States

Fig. 6

The cost-effectiveness scatter plot of the Markov model in China (A) and in the United States (B). X-axis: Incremental effectiveness (measured in QALYs). Y-axis: Incremental cost (measured in RMB for China and USD for the United States). Points: Each point represents a simulation result, showing the combination of incremental cost and effectiveness. Ellipse: Represents the 95% confidence interval of the simulation results. Dashed Line: Represents the willingness-to-pay (WTP) threshold (e.g., 150,000 RMB/QALY for China and 150,000 USD/QALY for the United States)

Back to article page

Cost Effectiveness and Resource Allocation

ISSN: 1478-7547

Contact us